A Umbrella Study in Relapsed/Refractory Peripheral T-cell Lymphoma Guided by Molecular Subtypes
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
This is a multicenter, prospective, open-label, interventional umbrella study to evaluate the efficacy and safety of targeted therapies guided by molecular subtypes in patients with relasped or refractory peripheral T-cell lymphoma.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Histologically-confirmed Peripheral T-cell lymphoma (without central nervous system involvement)
• Relapsed or refractory disease after first line treatment
• Availability of archival or freshly collected tumor tissue before study enrollment
• Evaluable lesion by PET-CT or CT scan
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
• Life expectancy greater than or equal to (\>/=) 3 months
• Informed consent
Locations
Other Locations
China
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITING
Shanghai
Contact Information
Primary
Weili Zhao
zwl_trial@163.com
+862164370045
Backup
Pengpeng Xu
pengpeng_xu@126.com
+862164370045
Time Frame
Start Date: 2022-09-30
Estimated Completion Date: 2026-01-26
Participants
Target number of participants: 116
Treatments
Experimental: T1 subtypes based on next generation sequencing results
T1 subtypes based on next generation sequencing results
Experimental: T2 subtypes based on next generation sequencing results
T2 subtypes based on next generation sequencing results
Experimental: T3.1 subtypes based on next generation sequencing results
T3.1 subtypes based on next generation sequencing results
Experimental: T3.2 subtypes based on next generation sequencing results
T3.2 subtypes based on next generation sequencing results
Related Therapeutic Areas
Sponsors
Leads: Ruijin Hospital